Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis

Inclusion Criteria: * Possible, probable (clinically or laboratory supported) or definite ALS according to the revised version of the El Escorial criteria (Brooks et al. 2000) * Disease duration \< 36 months * Vital capacity of more than 50% of normal (defined as slow vital capacity, best of three measurements) * Age ≥18 years * Continuously treated with 100 mg riluzole daily for at least four weeks * Capable of thoroughly understanding all information given and giving full informed consent according to GCP * Willing to complete a diet questionnaire throughout participation in the study Exclusion Criteria: * Simultaneous participation in another interventional clinical study * Previous participation in a drug clinical trial where last intake of the trial drug was within the last 12 weeks * Known sensitivity or intolerance to rape oil or sunflower oil, or components thereof * Tracheostomy * Patients with gastrostomy * Pregnancy or breastfeeding * Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS * Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment. * Evidence of a major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms. * Liable to be not cooperative or comply with study requirements as assessed by the investigator, or unable to be reached in the case of emergency.